The Journal of Immunology, Vol 142, Issue 7 2279-2289, Copyright © 1989 by American Association of Immunologists

ARTICLES

Human T cell leukemia/lymphoma virus type I infection of a CD4+ proliferative/cytotoxic T cell clone progresses in at least two distinct phases based on changes in function and phenotype of the infected cells

H Yssel, R de Waal Malefyt, MD Duc Dodon, D Blanchard, L Gazzolo, JE de Vries and H Spits
UNICET, Laboratory for Immunological Research, Dardilly, France.

The effect of human T cell leukemia/lymphoma virus type I (HTLV-I) infection on the function and the phenotype of a human proliferating/cytotoxic T cell clone, specific for tetanus toxin, was investigated. During the period after infection, two distinct phases were observed, based on growth properties, phenotype, and functional activity of the infected cells. Phase I HTLV-I infected cells (0 to about 150 days after infection) proliferated in an IL-2-dependent way, but without the requirement for repetitive antigenic stimulation. No differences in expression of the CD2, CD3, CD4, Tp103, and CD28 Ag between these cells and the parental cells could be demonstrated, with the exception of the expression of IL-R p55 and HLA-DR Ag, which were constitutively expressed on the phase I cells. The phase I HTLV-I- infected cells, as well as the parental 827 cells reacted with a mAb specific for an epitope on the variable part of the TCR beta-chain, indicating that the TCR was not altered after HTLV-I infection. Like the parental clone, the phase I cells proliferated in response to tetanus toxin, but the tetanus toxin-specific response of the phase I cells did not require the presence of APC. Results of experiments, in which the levels of intracellular Ca2+ were measured, indicated that HTLV-I cells can acquire the capability to process Ag and present that to themselves. Phase I HTLV-I-infected T cells had lost their cytotoxic activity which was likely to be due to an effect on the lytic machinery rather than on Ag recognition by the TCR, inasmuch as it was found that phase I HTLV-I-infected T cells did no longer contain N-alpha-benzyloxy- L-lysine thiobenzylester-serine esterase activity. Furthermore, it was found that phase I HTLV-I-infected T cells had a diminished capacity to form conjugates with target cells. From a period of about 200 days after HTLV-I infection, phase II cells emerged that proliferated strongly in the absence of IL-2 and that had lost all functional activity. These cells did not express the CD3/T cell receptor complex on their surface. Phase I as well as phase II HTLV-I-infected cells were targets for CTL raised in the autologous donor.

This article has been cited by other articles:

				B. M. Badran, K. Kunstman, J. Stanton, M. Moschitta, A. Zerghe, H. Akl, A. Burny, S. M. Wolinsky, and K. E. Willard-Gallo Transcriptional Regulation of the Human CD3{gamma} Gene: The TATA-Less CD3{gamma} Promoter Functions via an Initiator and Contiguous Sp-Binding Elements J. Immunol., May 15, 2005; 174(10): 6238 - 6249. [Abstract] [Full Text] [PDF]

				P. S. Torres, A. Alcover, D. A. Zapata, J. Arnaud, A. Pacheco, J. M. Martin-Fernandez, E. M. Villasevil, O. Sanal, and J. R. Regueiro TCR Dynamics in Human Mature T Lymphocytes Lacking CD3{gamma} J. Immunol., June 15, 2003; 170(12): 5947 - 5955. [Abstract] [Full Text] [PDF]

				B. M. Badran, S. M. Wolinsky, A. Burny, and K. E. Willard-Gallo Identification of Three NFAT Binding Motifs in the 5'-Upstream Region of the Human CD3gamma Gene That Differentially Bind NFATc1, NFATc2, and NF-kappa B p50 J. Biol. Chem., November 27, 2002; 277(49): 47136 - 47148. [Abstract] [Full Text] [PDF]

				C. Casoli, E. Vicenzi, A. Cimarelli, G. Magnani, P. Ciancianaini, E. Cattaneo, P. Dall'Aglio, G. Poli, and U. Bertazzoni HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1alpha Blood, May 1, 2000; 95(9): 2760 - 2769. [Abstract] [Full Text] [PDF]

				M. Suzuki, C. S. Dezzutti, A. Okayama, N. Tachibana, H. Tsubouchi, N. Mueller, and R. B. Lal Modulation of T-Cell Responses to a Recall Antigen in Human T-Cell Leukemia Virus Type 1-Infected Individuals Clin. Vaccine Immunol., September 1, 1999; 6(5): 713 - 717. [Abstract] [Full Text] [PDF]

				I. Segura, C. Delmelle-Wibaut, M. Janssens, Y. Cleuter, A. van den Broeke, R. Kettmann, and K. E. Willard-Gallo Human Immunodeficiency Virus Type 2 Produces a Defect in CD3-gamma Gene Transcripts Similar to That Observed for Human Immunodeficiency Virus Type 1 J. Virol., June 1, 1999; 73(6): 5207 - 5213. [Abstract] [Full Text]

				P. Hollsberg Mechanisms of T-Cell Activation by Human T-Cell Lymphotropic Virus Type I Microbiol. Mol. Biol. Rev., June 1, 1999; 63(2): 308 - 333. [Abstract] [Full Text] [PDF]

				N. Noraz, K. Saha, F. Ottones, S. Smith, and N. Taylor Cutting Edge: Constitutive Activation of TCR Signaling Molecules in IL-2-Independent Herpesvirus saimiri-Transformed T Cells J. Immunol., March 1, 1998; 160(5): 2042 - 2045. [Abstract] [Full Text] [PDF]

				T. Migone, J. Lin, A Cereseto, J. Mulloy, J. O'Shea, G Franchini, and W. Leonard Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I Science, July 7, 1995; 269(5220): 79 - 81. [Abstract] [PDF]

				B. Biesinger, A. Y. Tsygankov, H. Fickenscher, F. Emmrich, B. Fleckenstein, J. B. Bolen, and B. M. Bröker The Product of the Herpesvirus saimiri Open Reading Frame 1 (Tip) Interacts with T Cell-specific Kinase p56[IMAGE] in Transformed Cells J. Biol. Chem., March 3, 1995; 270(9): 4729 - 4734. [Abstract] [Full Text] [PDF]